TY - JOUR
T1 - Subthreshold laser therapy for diabetic macular edema
T2 - Metabolic and safety issues
AU - Vujosevic, Stela
AU - Martini, Ferdinando
AU - Convento, Enrica
AU - Longhin, Evelyn
AU - Kotsafti, Olympia
AU - Parrozzani, Raffaele
AU - Midena, Edoardo
PY - 2013/9
Y1 - 2013/9
N2 - Purpose: To review the most important metabolic effects and clinical safety data of subthreshold micropulse diode laser (D-MPL) in diabetic macular edema (DME). Methods: Review of the literature about the mechanisms of action and role of D-MPL in DME. Results: The MPL treatment does not damage the retina and is selectively absorbed by the retinal pigment epithelium (RPE). MPL stimulates secretion of different protective cytokines by the RPE. No visible laser spots on the retina were noted on any fundus image modality in different studies, and there were no changes of the outer retina integrity. Mean central retinal sensitivity (RS) increased in subthreshold micropulse diode laser group compared to standard ETDRS photocoagulation group. Conclusions: MPL is a new, promising treatment option in DME, with both infrared and yellow wavelengths using the less aggressive duty cycle (5%) and fixed power parameters. It appears to be safe from morphologic and functional point of view in mild center involving DME.
AB - Purpose: To review the most important metabolic effects and clinical safety data of subthreshold micropulse diode laser (D-MPL) in diabetic macular edema (DME). Methods: Review of the literature about the mechanisms of action and role of D-MPL in DME. Results: The MPL treatment does not damage the retina and is selectively absorbed by the retinal pigment epithelium (RPE). MPL stimulates secretion of different protective cytokines by the RPE. No visible laser spots on the retina were noted on any fundus image modality in different studies, and there were no changes of the outer retina integrity. Mean central retinal sensitivity (RS) increased in subthreshold micropulse diode laser group compared to standard ETDRS photocoagulation group. Conclusions: MPL is a new, promising treatment option in DME, with both infrared and yellow wavelengths using the less aggressive duty cycle (5%) and fixed power parameters. It appears to be safe from morphologic and functional point of view in mild center involving DME.
KW - Diabetic macular edema
KW - Diabetic retinopathy
KW - Fluorescein angiography
KW - Fundus autofluorescence
KW - Laser treatment
KW - Microperimetry
KW - Optical coherence tomography
KW - Retinal safety
KW - Subthreshold micropulse laser
UR - http://www.scopus.com/inward/record.url?scp=84883237476&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84883237476&partnerID=8YFLogxK
U2 - 10.2174/09298673113209990030
DO - 10.2174/09298673113209990030
M3 - Article
C2 - 23745552
AN - SCOPUS:84883237476
VL - 20
SP - 3267
EP - 3271
JO - Current Medicinal Chemistry
JF - Current Medicinal Chemistry
SN - 0929-8673
IS - 26
ER -